Jaguar Health explores strategic alternatives ahead of crofelemer NDA filing

Jaguar's board initiated a process to review strategic alternatives including mergers, acquisitions, and partnerships to maximize shareholder value as it completes clinical work for a rare disease intestinal failure drug. The move comes as crofelemer shows promise in reducing parenteral support by up to 37% in ongoing trials for microvillus inclusion disease.